title: Bone marrow transplantation for T-B- severe combined immunodeficiency disease in Athabascan-speaking native Americans.
abstract: A distinct form of autosomal recessive T-B- severe combined immunodeficiency disease occurs with a high frequency among Athabascan-speaking Native Americans (SCIDA), including Navajo and Apache Indians from the southwestern US and Dene Indians from the Canadian Northwest Territories. The SCIDA gene has been linked to markers on chromosome 10p although its identity and role in the pathogenesis of this disease are unknown. We report our experience in treating 18 Navajo and Dene children with SCIDA between 1984 and 1999; 16 underwent bone marrow transplants (BMT). All children were symptomatic within 2 months of birth, had the T-B- NK(+)SCID phenotype and 67% presented with oral and/or genital ulcers. Three children had evidence of maternal engraftment prior to transplant. Two children died shortly after diagnosis. Three children required more than one BMT and 12 are alive with T cell reconstitution at a median follow-up of 7 years. Three children developed normal B cell immunity, two of whom received ablative conditioning therapy with either radiation or busulfan. Three of the four children who died received therapy with either radiation or busulfan and two of eight long-term survivors who were also recipients of cytotoxic chemotherapy have failed to develop secondary teeth. These results demonstrate the efficacy of BMT in treating infants with this distinct form of SCID, although B cell reconstitution remains a problem even with HLA-matched donors. Without conditioning, T cell engraftment is likely when closely HLA-matched donors are used. With T cell depletion of haplocompatible marrow, conditioning with immunosuppressive therapy may be necessary; however, children with SCIDA who were treated with intensive immunosuppressive and myeloablative therapy had a poor outcome.
authors.affiliation: Department of Pediatrics Bone Marrow Transplant Division, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-1278, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: O'Marcaigh
authors.forename: K
authors.initials: K
authors.lastname: DeSantes
authors.forename: D
authors.initials: D
authors.lastname: Hu
authors.forename: H
authors.initials: H
authors.lastname: Pabst
authors.forename: B
authors.initials: B
authors.lastname: Horn
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: M J
authors.initials: MJ
authors.lastname: Cowan
mesh_terms: D001402:B-Lymphocytes; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000379:methods*; D002170:Canada; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006239:Haplotypes; D006648:Histocompatibility; D006801:Humans; D016130:Immunophenotyping; D007198:Indians, North American / Q000235:genetics*; D007223:Infant; D007231:Infant, Newborn; D008212:Lymphocyte Depletion; D008297:Male; D009679:Nuclear Family; D016511:Severe Combined Immunodeficiency / Q000150:complications / Q000628:therapy*; D013601:T-Lymphocytes; D014019:Tissue Donors; D016896:Treatment Outcome; D014481:United States